Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®

Cardiac sarcoidosis

William J McKenna, MD
Section Editor
Talmadge E King, Jr, MD
Deputy Editor
Susan B Yeon, MD, JD, FACC


Cardiac sarcoidosis can be a benign, incidentally discovered condition or a life-threatening disorder causing sudden death. Small observational registries and studies have described clinical evidence of myocardial involvement in 5 percent of patients with systemic sarcoidosis, yet autopsy studies indicate that subclinical cardiac involvement is present in up to 70 percent of cases. These observations suggest that the diagnosis of cardiac sarcoidosis is difficult to establish, especially in patients without evidence of sarcoid in other organs and thus cardiac sarcoidosis is often underdiagnosed in every day clinical practice. Furthermore, there is neither a clear-cut understanding of the underlying pathophysiology and progression of this disease, nor a consensus on the optimal methods for disease detection, monitoring, and treatment.

There appear to be differences in the presentation of cardiac sarcoidosis among various countries, although comparison among studies is limited by differing methodologies. In the United States, 13 to 25 percent of deaths from sarcoidosis have been attributed to cardiac sarcoidosis while in Japan, 47 to 85 percent of deaths from sarcoidosis have been attributed to cardiac involvement. In contrast, a retrospective study from Haifa, Israel reported that only 2 of 120 patients with sarcoidosis died of cardiac involvement [1].

This report reviews the latest understanding of cardiac sarcoidosis, providing details on the pertinent clinical features, methods used in the diagnosis and monitoring of disease progression and in the management of this condition. General issues related to systemic sarcoidosis are discussed separately. The American Thoracic Society (ATS) statement on sarcoidosis [2] can be accessed through the ATS web site. (See "Clinical manifestations and diagnosis of pulmonary sarcoidosis" and "Pathogenesis of sarcoidosis".)


Sarcoidosis is a heterogeneous, non-caseating, granulomatous disorder of unknown etiology that can involve any organ within the body. Cardiac involvement may be detected alone and may precede, follow, or occur concurrently with other organ (eg, lung) involvement. As an example, a German study of 52 patients with evidence of sarcoid heart disease found that one-third had normalized lung changes [3].

There are geographic variations in the epidemiology and presentation of cardiac sarcoidosis. Japanese pathologists report cardiac involvement in as many as 50 to 78 percent, whereas in the United States, 13 to 50 percent of all deaths are related to cardiac involvement [4-10]. A retrospective study from Israel interestingly demonstrated that only 2 of 120 patients (2 percent) with sarcoidosis died from cardiac involvement [1].


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Dec 2016. | This topic last updated: Fri Apr 29 00:00:00 GMT+00:00 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Yigla M, Badarna-Abu-Ria N, Tov N, et al. Sarcoidosis in northern Israel; clinical characteristics of 120 patients. Sarcoidosis Vasc Diffuse Lung Dis 2002; 19:220.
  2. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. Am J Respir Crit Care Med 1999; 160:736.
  3. Schulte W, Kirsten D, Drent M, Costabel U. Cardiac involvement in sarcoidosis. Eur Respir Mon 2005; 32:130.
  4. Chapelon-Abric C, de Zuttere D, Duhaut P, et al. Cardiac sarcoidosis: a retrospective study of 41 cases. Medicine (Baltimore) 2004; 83:315.
  5. Kim JS, Judson MA, Donnino R, et al. Cardiac sarcoidosis. Am Heart J 2009; 157:9.
  6. Thomsen TK, Eriksson T. Myocardial sarcoidosis in forensic medicine. Am J Forensic Med Pathol 1999; 20:52.
  7. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Cardiac involvement in patients with pulmonary sarcoidosis assessed at two university medical centers in the Netherlands. Chest 2005; 128:30.
  8. Yoshida Y, Morimoto S, Hiramitsu S, et al. Incidence of cardiac sarcoidosis in Japanese patients with high-degree atrioventricular block. Am Heart J 1997; 134:382.
  9. Fleming H. Cardiac Sarcoidosis. In: Sarcoidosis and Other Granulomatous Disorders, James DG. (Ed), Dekker, New York 1994. p.323.
  10. Sekiguchi M, Numao Y, Imai M, et al. Clinical and histopathological profile of sarcoidosis of the heart and acute idiopathic myocarditis. Concepts through a study employing endomyocardial biopsy. I. Sarcoidosis. Jpn Circ J 1980; 44:249.
  11. Patel MR, Cawley PJ, Heitner JF, et al. Detection of myocardial damage in patients with sarcoidosis. Circulation 2009; 120:1969.
  12. Schaedel H, Kirsten D, Schmidt A, et al. Sarcoid heart disease--results of follow-up investigations. Eur Heart J 1991; 12 Suppl D:26.
  13. Mehta D, Lubitz SA, Frankel Z, et al. Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 2008; 133:1426.
  14. Judson MA, Baughman RP, Teirstein AS, et al. Defining organ involvement in sarcoidosis: the ACCESS proposed instrument. ACCESS Research Group. A Case Control Etiologic Study of Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16:75.
  15. Yazaki Y, Isobe M, Hiramitsu S, et al. Comparison of clinical features and prognosis of cardiac sarcoidosis and idiopathic dilated cardiomyopathy. Am J Cardiol 1998; 82:537.
  16. Ayyala US, Nair AP, Padilla ML. Cardiac sarcoidosis. Clin Chest Med 2008; 29:493.
  17. Iwai K, Sekiguti M, Hosoda Y, et al. Racial difference in cardiac sarcoidosis incidence observed at autopsy. Sarcoidosis 1994; 11:26.
  18. Goyal SB, Aragam JR. Cardiac sarcoidosis with primary involvement of the tricuspid valve. Cardiol Rev 2006; 14:e12.
  19. Gasparovic H, Bueno R, Rybicki FJ, et al. Sarcoidosis of the aortic root. J Thorac Cardiovasc Surg 2004; 128:761.
  20. Weiler V, Redtenbacher S, Bancher C, et al. Concurrence of sarcoidosis and aortitis: case report and review of the literature. Ann Rheum Dis 2000; 59:850.
  21. Gedalia A, Shetty AK, Ward K, et al. Abdominal aortic aneurysm associated with childhood sarcoidosis. J Rheumatol 1996; 23:757.
  22. Shimada T, Shimada K, Sakane T, et al. Diagnosis of cardiac sarcoidosis and evaluation of the effects of steroid therapy by gadolinium-DTPA-enhanced magnetic resonance imaging. Am J Med 2001; 110:520.
  23. Smedema JP, Snoep G, van Kroonenburgh MP, et al. The additional value of gadolinium-enhanced MRI to standard assessment for cardiac involvement in patients with pulmonary sarcoidosis. Chest 2005; 128:1629.
  24. Roberts WC, Chung MS, Ko JM, et al. Morphologic features of cardiac sarcoidosis in native hearts of patients having cardiac transplantation. Am J Cardiol 2014; 113:706.
  25. Currie GP, Kerr K, Buchan K, Garg D. A rare cause of recurrent massive pericardial and pleural effusions. QJM 2008; 101:989.
  26. Kinney E, Murthy R, Ascunce G, et al. Pericardial effusions in sarcoidosis. Chest 1979; 76:476.
  27. Abrishami B, O'Connel C, Sharma O. Cardiac sarcoidosis with presentation of large left atrial mass. Curr Opin Pulm Med 2004; 10:397.
  28. Uchida M, Shinohara T, Takahashi N, Saikawa T. Interventricular septal mass in a patient with cardiac sarcoidosis. J Cardiovasc Electrophysiol 2012; 23:433.
  29. Soejima K, Yada H. The work-up and management of patients with apparent or subclinical cardiac sarcoidosis: with emphasis on the associated heart rhythm abnormalities. J Cardiovasc Electrophysiol 2009; 20:578.
  30. Hamzeh NY, Wamboldt FS, Weinberger HD. Management of cardiac sarcoidosis in the United States: a Delphi study. Chest 2012; 141:154.
  31. Youssef G, Beanlands RS, Birnie DH, Nery PB. Cardiac sarcoidosis: applications of imaging in diagnosis and directing treatment. Heart 2011; 97:2078.
  32. Yeboah J, Lee C, Sharma OP. Cardiac sarcoidosis: a review 2011. Curr Opin Pulm Med 2011; 17:308.
  33. Nery PB, Leung E, Birnie DH. Arrhythmias in cardiac sarcoidosis: diagnosis and treatment. Curr Opin Cardiol 2012; 27:181.
  34. Barbou F, Lahutte M, Gontier E. Cardiac sarcoidosis presenting as an arrhythmogenic right ventricular cardiomyopathy. Heart 2012; 98:1753.
  35. Dechering DG, Kochhäuser S, Wasmer K, et al. Electrophysiological characteristics of ventricular tachyarrhythmias in cardiac sarcoidosis versus arrhythmogenic right ventricular cardiomyopathy. Heart Rhythm 2013; 10:158.
  36. Suzuki T, Kanda T, Kubota S, et al. Holter monitoring as a noninvasive indicator of cardiac involvement in sarcoidosis. Chest 1994; 106:1021.
  37. Fahy GJ, Marwick T, McCreery CJ, et al. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109:62.
  38. Sun BJ, Lee PH, Choi HO, et al. Prevalence of echocardiographic features suggesting cardiac sarcoidosis in patients with pacemaker or implantable cardiac defibrillator. Korean Circ J 2011; 41:313.
  39. Sekiguchi M, Yazaki Y, Isobe M, Hiroe M. Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations. Cardiovasc Drugs Ther 1996; 10:495.
  40. Smedema JP, Snoep G, van Kroonenburgh MP, et al. Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 2005; 45:1683.
  41. Tadamura E, Yamamuro M, Kubo S, et al. Effectiveness of delayed enhanced MRI for identification of cardiac sarcoidosis: comparison with radionuclide imaging. AJR Am J Roentgenol 2005; 185:110.
  42. Vignaux O, Dhote R, Duboc D, et al. Clinical significance of myocardial magnetic resonance abnormalities in patients with sarcoidosis: a 1-year follow-up study. Chest 2002; 122:1895.
  43. Sharma S. Cardiac imaging in myocardial sarcoidosis and other cardiomyopathies. Curr Opin Pulm Med 2009; 15:507.
  44. Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging 2013; 6:501.
  45. Ishimaru S, Tsujino I, Sakaue S, et al. Combination of 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in assessing cardiac sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22:234.
  46. Youssef G, Leung E, Mylonas I, et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012; 53:241.
  47. Langah R, Spicer K, Gebregziabher M, Gordon L. Effectiveness of prolonged fasting 18f-FDG PET-CT in the detection of cardiac sarcoidosis. J Nucl Cardiol 2009; 16:801.
  48. Okumura W, Iwasaki T, Toyama T, et al. Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 2004; 45:1989.
  49. Ohira H, Tsujino I, Ishimaru S, et al. Myocardial imaging with 18F-fluoro-2-deoxyglucose positron emission tomography and magnetic resonance imaging in sarcoidosis. Eur J Nucl Med Mol Imaging 2008; 35:933.
  50. Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 2014; 63:329.
  51. Tadamura E, Yamamuro M, Kubo S, et al. Images in cardiovascular medicine. Multimodality imaging of cardiac sarcoidosis before and after steroid therapy. Circulation 2006; 113:e771.
  52. Sato Y, Matsumoto N, Kunimasa T, et al. Multiple involvements of cardiac sarcoidosis in both left and right ventricles and papillary muscles detected by delayed-enhanced magnetic resonance imaging. Int J Cardiol 2008; 130:288.
  53. Haywood LJ, Sharma OP, Siegel ME, et al. Detection of myocardial sarcoidosis by thallium 201 imaging. J Natl Med Assoc 1982; 74:959.
  54. Eguchi M, Tsuchihashi K, Hotta D, et al. Technetium-99m sestamibi/tetrofosmin myocardial perfusion scanning in cardiac and noncardiac sarcoidosis. Cardiology 2000; 94:193.
  55. Nakazawa A, Ikeda K, Ito Y, et al. Usefulness of dual 67Ga and 99mTc-sestamibi single-photon-emission CT scanning in the diagnosis of cardiac sarcoidosis. Chest 2004; 126:1372.
  56. Okayama K, Kurata C, Tawarahara K, et al. Diagnostic and prognostic value of myocardial scintigraphy with thallium-201 and gallium-67 in cardiac sarcoidosis. Chest 1995; 107:330.
  57. Pandya C, Brunken RC, Tchou P, et al. Detecting cardiac involvement in sarcoidosis: a call for prospective studies of newer imaging techniques. Eur Respir J 2007; 29:418.
  58. Smedema JP, White L, Klopper AJ. FDG-PET and MIBI-Tc SPECT as follow-up tools in a patient with cardiac sarcoidosis requiring a pacemaker. Cardiovasc J Afr 2008; 19:309.
  59. Wait JL, Movahed A. Anginal chest pain in sarcoidosis. Thorax 1989; 44:391.
  60. Rubinstein I, Fisman EZ, Rosenblum Y, et al. Left-ventricular exercise echocardiographic abnormalities in patients with sarcoidosis without ischemic heart disease. Isr J Med Sci 1986; 22:865.
  61. Ardic I, Kaya MG, Yarlioglues M, et al. Impaired heart rate recovery index in patients with sarcoidosis. Chest 2011; 139:60.
  62. Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138:1078.
  63. Uemura A, Morimoto S, Hiramitsu S, et al. Histologic diagnostic rate of cardiac sarcoidosis: evaluation of endomyocardial biopsies. Am Heart J 1999; 138:299.
  64. Asimaki A, Tandri H, Huang H, et al. A new diagnostic test for arrhythmogenic right ventricular cardiomyopathy. N Engl J Med 2009; 360:1075.
  65. Asimaki A, Tandri H, Duffy ER, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. Circ Arrhythm Electrophysiol 2011; 4:743.
  66. Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 51:e1.
  67. Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol 2005; 96:276.
  68. Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sudden cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol 2011; 4:43.
  69. Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm 2014; 11:1305.
  70. Takada K, Ina Y, Yamamoto M, et al. Prognosis after pacemaker implantation in cardiac sarcoidosis in Japan. Clinical evaluation of corticosteroid therapy. Sarcoidosis 1994; 11:113.
  71. Yazaki Y, Isobe M, Hiroe M, et al. Prognostic determinants of long-term survival in Japanese patients with cardiac sarcoidosis treated with prednisone. Am J Cardiol 2001; 88:1006.
  72. Belhassen B, Pines A, Laniado S. Failure of corticosteroid therapy to prevent induction of ventricular tachycardia in sarcoidosis. Chest 1989; 95:918.
  73. Winters SL, Cohen M, Greenberg S, et al. Sustained ventricular tachycardia associated with sarcoidosis: assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia device. J Am Coll Cardiol 1991; 18:937.
  74. Reuhl J, Schneider M, Sievert H, et al. Myocardial sarcoidosis as a rare cause of sudden cardiac death. Forensic Sci Int 1997; 89:145.
  75. Roberts WC, McAllister HA Jr, Ferrans VJ. Sarcoidosis of the heart. A clinicopathologic study of 35 necropsy patients (group 1) and review of 78 previously described necropsy patients (group 11). Am J Med 1977; 63:86.
  76. Betensky BP, Tschabrunn CM, Zado ES, et al. Long-term follow-up of patients with cardiac sarcoidosis and implantable cardioverter-defibrillators. Heart Rhythm 2012; 9:884.
  77. Bajaj AK, Kopelman HA, Echt DS. Cardiac sarcoidosis with sudden death: treatment with the automatic implantable cardioverter defibrillator. Am Heart J 1988; 116:557.
  78. Paz HL, McCormick DJ, Kutalek SP, Patchefsky A. The automated implantable cardiac defibrillator. Prophylaxis in cardiac sarcoidosis. Chest 1994; 106:1603.
  79. Jefic D, Joel B, Good E, et al. Role of radiofrequency catheter ablation of ventricular tachycardia in cardiac sarcoidosis: report from a multicenter registry. Heart Rhythm 2009; 6:189.
  80. Koplan BA, Soejima K, Baughman K, et al. Refractory ventricular tachycardia secondary to cardiac sarcoid: electrophysiologic characteristics, mapping, and ablation. Heart Rhythm 2006; 3:924.
  81. Zaidi AR, Zaidi A, Vaitkus PT. Outcome of heart transplantation in patients with sarcoid cardiomyopathy. J Heart Lung Transplant 2007; 26:714.
  82. Perkel D, Czer LS, Morrissey RP, et al. Heart transplantation for end-stage heart failure due to cardiac sarcoidosis. Transplant Proc 2013; 45:2384.
  83. Valantine HA, Tazelaar HD, Macoviak J, et al. Cardiac sarcoidosis: response to steroids and transplantation. J Heart Transplant 1987; 6:244.
  84. Oni AA, Hershberger RE, Norman DJ, et al. Recurrence of sarcoidosis in a cardiac allograft: control with augmented corticosteroids. J Heart Lung Transplant 1992; 11:367.